Outpost Medicine

Clinical-stage biopharmaceutical company addressing unmet needs in urologic and gastrointestinal disorders

Outpost Medicine is a Frazier-founded company focused on developing novel therapeutics for the treatment of urologic and gastrointestinal disorders. The company’s lead clinical-stage product candidate (OP-687) is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Outpost is also developing OP-352, which was licensed from Arena Pharmaceuticals in 2018, for the treatment of stress urinary incontinence and fecal incontinence.

Year of Investment

2016

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Boston, Massachusetts